Media type: E-Article Title: Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors Contributor: Kühnel, Line; Raket, Lars Lau; Åström, Daniel Oudin; Berger, Anna‐Karin; Hansen, Ingeborg Helbech; Krismer, Florian; Wenning, Gregor K.; Seppi, Klaus; Poewe, Werner; Molinuevo, JoséLuis Published: Wiley, 2022 Published in: Movement Disorders, 37 (2022) 8, Seite 1719-1727 Language: English DOI: 10.1002/mds.29077 ISSN: 0885-3185; 1531-8257 Keywords: Neurology (clinical) ; Neurology Origination: Footnote: Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Multiple system atrophy (MSA) is a rare and aggressive neurodegenerative disease that typically leads to death 6 to 10 years after symptom onset. The rapid evolution renders it crucial to understand the general disease progression and factors affecting the disease course.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>The aims of this study were to develop a novel disease‐progression model to estimate a population‐level MSA progression trajectory and predict patient‐specific continuous disease stages describing the degree of progress into the disease.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The disease‐progression model estimated a population‐level progression trajectory of subscales of the Unified MSA Rating Scale and the Unified Parkinson's Disease Rating Scale using patients in the European MSA natural history study. The predicted disease continuum was validated via multiple analyses based on reported anchor points, and the effect of MSA subtype on the rate of disease progression was evaluated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The predicted disease continuum spanned approximately 6 years, with an estimated average duration of 51 months for a patient with global disability score 0 to reach the highest level of 4. The predicted continuous disease stages were shown to be correlated with time of symptom onset and predictive of survival time. MSA motor subtype was found to significantly affect disease progression, with MSA‐parkinsonian (MSA‐P) type patients having an accelerated rate of progression.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The proposed modeling framework introduces a new method of analyzing and interpreting the progression of MSA. It can provide new insights and opportunities for investigating covariate effects on the rate of progression and provide well‐founded predictions of patient‐level future progressions. © 2022 The Authors. <jats:italic>Movement Disorders</jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society</jats:p></jats:sec>